What are the side effects of inhaled ipratropium bromide?

Side Effects of Inhaled Ipratropium Bromide

Inhaled ipratropium bromide is generally well-tolerated with minimal systemic side effects due to its poor absorption across biological membranes, with the most common adverse events being mild and local: epistaxis (9% vs 5% with saline) and nasal dryness (5% vs 1% with saline) for intranasal formulations, and dry mouth, cough, and respiratory symptoms for inhaled formulations. 1, 2

Most Common Side Effects (Inhaled Formulations)

Respiratory Effects

• Cough occurs in 4.6-8.0% of patients using nebulized ipratropium 2
• Dyspnea is reported in 9.6-16.7% of patients, though this may reflect underlying disease rather than drug effect 2
• Bronchospasm occurs in 2.3-5.4% of patients, with rare cases of paradoxical bronchoconstriction 2, 3
• Bronchitis is reported in 14.6-24.5% of patients, likely reflecting disease progression rather than drug toxicity 2

Anticholinergic Effects

• Dry mouth occurs in 0-3.2% of patients with inhaled formulations (significantly lower than with oral anticholinergics) 2, 4
• The quaternary ammonium structure of ipratropium results in minimal systemic absorption, thereby reducing classic anticholinergic effects (neurologic, ophthalmic, cardiovascular, gastrointestinal) seen with tertiary anticholinergic compounds 1

Other Common Effects

• Headache is reported in 6.4-9.0% of patients 2
• Nausea occurs in 1.9-4.1% of patients 2
• Dizziness affects 1.9-4.0% of patients 2

Serious but Rare Adverse Events

Cardiovascular Concerns

• Increased cardiovascular events have been reported in some studies, with a hazard ratio of 1.40 (95% CI 1.30-1.51) for recent use (within 6 months) in COPD patients 5
• Arrhythmias show an increased risk in younger patients (12-24 years) with asthma, with an adjusted odds ratio of 1.56 (95% CI 1.08-2.25) for active users 6
• Risk appears dose-dependent, with high-dose users (>0.114 mg ipratropium equivalents) showing a 69% increased risk of arrhythmias 6
• Tachycardia and palpitations are reported in less than 3% of patients 2

Hypersensitivity Reactions

• Immediate hypersensitivity reactions including urticaria, angioedema of tongue/lips/face, rash, bronchospasm, laryngospasm, and anaphylaxis have been reported, particularly in patients with prior drug or food allergies 2

Ocular Effects

• Acute narrow-angle glaucoma and eye pain can occur if the medication reaches the eyes, particularly with nebulizer mask use 1
• Use a mouthpiece rather than a face mask in elderly patients or those at risk for glaucoma to minimize ocular exposure 1, 7

Urinary Effects

• Urinary retention is reported in less than 3% of patients, particularly relevant in elderly males with prostatic hypertrophy 1, 2

Special Population Considerations

Elderly Patients

• Ipratropium should be used with caution in patients with pre-existing glaucoma or prostatic hypertrophy 1
• The first dose should be supervised because beta-agonists in combination products may rarely precipitate angina 1, 7

Pediatric Patients

• The safety profile in children is similar to adults, with the 0.06% concentration demonstrated safe in children with upper respiratory infections 1

Cystic Fibrosis Patients

• Paradoxical decreases in FEV₁ of less than 10% may occur in isolated patients with cystic fibrosis 8

Important Safety Notes

Physiologic Functions Preserved

• Ipratropium does not alter normal nasal physiologic functions including sense of smell, ciliary beat frequency, mucociliary clearance, or the air conditioning capacity of the nose 1

Dose-Related Toxicity

• Headache, mouth dryness, and aggravation of COPD symptoms are more common when total daily dose equals or exceeds 2,000 mcg 2

Combination Therapy Safety

• Concomitant use with antihistamines or intranasal corticosteroids provides increased efficacy without any increase in adverse events 1

Paradoxical Bronchoconstriction

• True paradoxical bronchoconstriction to ipratropium is rare, occurring in only 1 of 50 patients (2%) in controlled studies, and may represent nonspecific bronchial hyperresponsiveness rather than a drug-specific effect 3